{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"retatrutide-ibd","title":"Retatrutide for IBD (Crohn's / Colitis): Metabolic Load Evidence and Limits","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves chronic gut inflammation that can lead to flares, tissue damage, and complications like strictures or fistulas in Crohn's or continuous mucosal inflammation in colitis. Excess body weight often co-occurs and adds mechanical stress to joints and spine while potentially worsening systemic inflammation. Repair pathways struggle when degeneration from repeated flares outpaces healing. No direct peptide targets the primary gut layer here; compounds are examined for indirect effects on load or metabolism.\n\n## Why Retatrutide might help you\n\n1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\n2. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\n3. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n4. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nIf your IBD profile includes obesity as a comorbidity, the weight-loss pathway studied with retatrutide could reduce overall mechanical burden on the body. This addresses one degenerative layer without claiming any direct action on intestinal mucosa or immune cells in the gut. Human data on retatrutide itself remains limited to metabolic outcomes; any IBD link stays indirect via load reduction.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Retatrutide** → metabolic load / body weight\n\nRetatrutide focuses solely on the metabolic load layer in this framing. Other potential layers in IBD, such as direct mucosal repair or inflammation control, would require separate compounds if stacked later. The approach avoids overlap by isolating weight-related mechanical factors from gut-specific degeneration.\n\n## What the evidence actually shows\n\nHuman trials for retatrutide show substantial weight loss but no dedicated IBD endpoints. A phase 2 study in adults with obesity reported up to 24.2% body weight reduction at 48 weeks with the 12 mg dose versus 2.1% on placebo (human tier). Phase 3 topline data indicated up to 30% loss at longer follow-up in severe obesity cohorts (human tier). These confirm metabolic effects but do not test Crohn's or colitis activity.\n\nGLP-1 class observational data in IBD patients (mostly semaglutide or liraglutide) show weight loss of roughly 9-12 kg at 3 months and, in some cohorts, lower rates of surgery or hospitalization, especially in obese subgroups (human tier, observational). One cohort found no change in IBD activity despite >6% weight loss, with common nausea (human tier). Preclinical animal models of colitis suggest GLP-1 signaling may reduce inflammation markers, but retatrutide-specific rat or mouse IBD studies are absent (preclinical tier for class only).\n\nReddit threads discuss users with Crohn's inquiring about retatrutide compatibility or side effects, with no controlled reports (anecdotal tier). X posts mirror this pattern of personal queries without outcome data (anecdotal tier).\n\n## What scientists say\n\nReviews note GLP-1 agonists achieve weight loss in IBD populations with a safety profile similar to non-IBD groups, while calling for prospective RCTs to test anti-inflammatory or disease-modifying effects (mechanistic/speculative tier beyond weight). No statements endorse retatrutide specifically for IBD remission or repair.\n\n## What people say on Reddit\n\nUsers in retatrutide communities ask about Crohn's interactions or complications, citing personal research but no shared trial-level outcomes. Posts remain exploratory rather than testimonial of benefit or harm (anecdotal tier).\n\n## What people say on X\n\nSimilar anecdotal queries appear around retatrutide use alongside IBD diagnoses, focused on tolerability rather than measured improvements in gut symptoms (anecdotal tier).\n\n## What we do not know\n\nNo human trials exist for retatrutide in active IBD. Direct effects on mucosal healing, flare frequency, or steroid needs remain untested. Long-term IBD-specific safety data are absent. Weight-loss benefits do not automatically translate to gut repair.\n\n## Safety and limits\n\nRetatrutide human trials report gastrointestinal side effects as most common, dose-related, and often mild to moderate. Heart rate increases occurred in a dose-dependent pattern that later declined. In IBD observational work on the class, nausea and diarrhea appeared frequently, sometimes leading to discontinuation. Evidence does not establish retatrutide as a repair agent for IBD inflammation; any role stays limited to metabolic load considerations in comorbid obesity. All claims require professional medical context; this is evidence inventory only.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/retatrutide-ibd/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Retatrutide produced up to 24.2% weight loss at 48 weeks in phase 2 obesity trial versus 2.1% placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes metabolic effect magnitude in humans without IBD endpoints.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Phase 3 retatrutide data showed up to 30% body weight reduction at 104 weeks in severe obesity.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Confirms larger-scale weight loss results relevant to load reduction discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Observational GLP-1 studies in IBD patients report 9-12 kg weight loss at 3 months and variable reductions in surgery/hospitalization risk in obese subgroups.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Provides closest human data class-level link to IBD comorbidities.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"One IBD obesity cohort found no effect on disease activity despite weight loss, with high nausea rates.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Highlights limits of extrapolating weight loss to IBD repair.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Preclinical colitis models suggest GLP-1 class anti-inflammatory signaling but no retatrutide-specific animal IBD data exist.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Separates class mechanistic signals from retatrutide evidence gap.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit and X discussions on retatrutide with Crohn's are limited to user queries about compatibility, with no outcome data shared.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s6"],"source_status":"sourced","why_material":"Documents real-world interest level without controlled evidence.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide... the 12-mg group... −24.2%","summary":"Phase 2 trial results showing dose-dependent weight loss with retatrutide.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:58:10.557Z","link_status":"http_403","quote_status":"unverified","prev":"genesis","hash":"a278d79912605fda4a8b1833d791a752f07a55cd49adb341da3f2aafdbd3b959"},{"id":"s2","type":"news","url":"https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss","title":"Phase III retatrutide study demonstrates 30% weight loss","quote":"participants with severe obesity who took retatrutide 9mg or 12mg achieved up to 30% weight loss... at 104 weeks","summary":"Topline phase 3 weight loss outcomes for retatrutide.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:58:10.557Z","link_status":"ok","quote_status":"unverified","prev":"a278d79912605fda4a8b1833d791a752f07a55cd49adb341da3f2aafdbd3b959","hash":"969ea15592ef8437d2eeb4490435da8256925e98b367e754eb48c821ebd7bace"},{"id":"s3","type":"pubmed","url":"https://academic.oup.com/ecco-jcc/article/19/10/jjaf181/8280408","title":"Glucagon-like peptide 1 receptor agonists and the clinical course of IBD","quote":"Weight loss was achieved using semaglutide (−9.6 kg... tirzepatide (−11.8 kg... GLP1-RAs were associated with lower risk of surgery... and reduced risk of hospitalization in the subset of obese patients","summary":"Meta-analysis of GLP-1 RAs in IBD showing weight and outcome associations.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:58:10.557Z","link_status":"http_403","quote_status":"unverified","prev":"969ea15592ef8437d2eeb4490435da8256925e98b367e754eb48c821ebd7bace","hash":"5dfe4d4b3d50561d1fabb13528147a5f27348c1929023d00bd7300286ab88dc7"},{"id":"s4","type":"medical","url":"https://resources.healthgrades.com/pro/the-potential-for-glp-1s-in-the-treatment-of-crohns-disease","title":"The Potential for GLP-1s in the Treatment of Crohn's Disease","quote":"these patients successfully lost more than 6% of their body weight, but the treatment had no effect on IBD activity... nausea was very common and one patient withdrew due to diarrhea","summary":"Cohort study noting weight loss without IBD activity change and GI side effects.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:58:10.557Z","link_status":"ok","quote_status":"unverified","prev":"5dfe4d4b3d50561d1fabb13528147a5f27348c1929023d00bd7300286ab88dc7","hash":"fcc1f8e2d5592f810cd6818261e17a3d985c03bf387cde530f81d20b8ae452c9"},{"id":"s5","type":"review","url":"https://www.mdpi.com/2227-9059/13/5/1128","title":"GLP-1R Agonists and Their Therapeutic Potential in Inflammatory Bowel Disease","quote":"there is a wealth of pre-clinical animal data suggesting that GLP-1RAs can ameliorate experimental colitis... lack of prospective clinical studies","summary":"Systematic review contrasting preclinical colitis signals with clinical evidence gaps.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:58:10.557Z","link_status":"http_403","quote_status":"unverified","prev":"fcc1f8e2d5592f810cd6818261e17a3d985c03bf387cde530f81d20b8ae452c9","hash":"1849c741dafdfb9c2b59b02901baedb908ec76cec11fe5df6ce78d482e1ac86d"},{"id":"s6","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1q37uvg/reta_with_crohns/","title":"reta with crohns","quote":"i was wondering if anyone knew about any complications for if i take reta while having crohn's disease or any other IBD","summary":"User inquiry on retatrutide compatibility with Crohn's, no outcome data.","claim_ids":["c6"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:58:10.557Z","link_status":"ok","quote_status":"unverified","prev":"1849c741dafdfb9c2b59b02901baedb908ec76cec11fe5df6ce78d482e1ac86d","hash":"fa4eec819108b622ddca30941d07f39e7025fbcafbb6b1135fb29258f8b7f446"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:58:12.137Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Retatrutide for IBD (Crohn's / Colitis): Metabolic Load Evidence and Limits","register":"source_ledger","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves chronic gut inflammation that can lead to flares, tissue damage, and complications like strictures or fistulas in Crohn's or continuous mucosal inflammation in colitis. Excess body weight often co-occurs and adds mechanical stress to joints and spine while potentially worsening systemic inflammation. Repair pathways struggle when degeneration from repeated flares outpaces healing. No direct peptide targets the primary gut layer here; compounds are examined for indirect effects on load or metabolism.\n\n## Why Retatrutide might help you\n\n1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\n2. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\n3. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n4. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nIf your IBD profile includes obesity as a comorbidity, the weight-loss pathway studied with retatrutide could reduce overall mechanical burden on the body. This addresses one degenerative layer without claiming any direct action on intestinal mucosa or immune cells in the gut. Human data on retatrutide itself remains limited to metabolic outcomes; any IBD link stays indirect via load reduction.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Retatrutide** → metabolic load / body weight\n\nRetatrutide focuses solely on the metabolic load layer in this framing. Other potential layers in IBD, such as direct mucosal repair or inflammation control, would require separate compounds if stacked later. The approach avoids overlap by isolating weight-related mechanical factors from gut-specific degeneration.\n\n## What the evidence actually shows\n\nHuman trials for retatrutide show substantial weight loss but no dedicated IBD endpoints. A phase 2 study in adults with obesity reported up to 24.2% body weight reduction at 48 weeks with the 12 mg dose versus 2.1% on placebo (human tier). Phase 3 topline data indicated up to 30% loss at longer follow-up in severe obesity cohorts (human tier). These confirm metabolic effects but do not test Crohn's or colitis activity.\n\nGLP-1 class observational data in IBD patients (mostly semaglutide or liraglutide) show weight loss of roughly 9-12 kg at 3 months and, in some cohorts, lower rates of surgery or hospitalization, especially in obese subgroups (human tier, observational). One cohort found no change in IBD activity despite >6% weight loss, with common nausea (human tier). Preclinical animal models of colitis suggest GLP-1 signaling may reduce inflammation markers, but retatrutide-specific rat or mouse IBD studies are absent (preclinical tier for class only).\n\nReddit threads discuss users with Crohn's inquiring about retatrutide compatibility or side effects, with no controlled reports (anecdotal tier). X posts mirror this pattern of personal queries without outcome data (anecdotal tier).\n\n## What scientists say\n\nReviews note GLP-1 agonists achieve weight loss in IBD populations with a safety profile similar to non-IBD groups, while calling for prospective RCTs to test anti-inflammatory or disease-modifying effects (mechanistic/speculative tier beyond weight). No statements endorse retatrutide specifically for IBD remission or repair.\n\n## What people say on Reddit\n\nUsers in retatrutide communities ask about Crohn's interactions or complications, citing personal research but no shared trial-level outcomes. Posts remain exploratory rather than testimonial of benefit or harm (anecdotal tier).\n\n## What people say on X\n\nSimilar anecdotal queries appear around retatrutide use alongside IBD diagnoses, focused on tolerability rather than measured improvements in gut symptoms (anecdotal tier).\n\n## What we do not know\n\nNo human trials exist for retatrutide in active IBD. Direct effects on mucosal healing, flare frequency, or steroid needs remain untested. Long-term IBD-specific safety data are absent. Weight-loss benefits do not automatically translate to gut repair.\n\n## Safety and limits\n\nRetatrutide human trials report gastrointestinal side effects as most common, dose-related, and often mild to moderate. Heart rate increases occurred in a dose-dependent pattern that later declined. In IBD observational work on the class, nausea and diarrhea appeared frequently, sometimes leading to discontinuation. Evidence does not establish retatrutide as a repair agent for IBD inflammation; any role stays limited to metabolic load considerations in comorbid obesity. All claims require professional medical context; this is evidence inventory only.","claims":[{"id":"c1","text":"Retatrutide produced up to 24.2% weight loss at 48 weeks in phase 2 obesity trial versus 2.1% placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes metabolic effect magnitude in humans without IBD endpoints.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Phase 3 retatrutide data showed up to 30% body weight reduction at 104 weeks in severe obesity.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Confirms larger-scale weight loss results relevant to load reduction discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Observational GLP-1 studies in IBD patients report 9-12 kg weight loss at 3 months and variable reductions in surgery/hospitalization risk in obese subgroups.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Provides closest human data class-level link to IBD comorbidities.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"One IBD obesity cohort found no effect on disease activity despite weight loss, with high nausea rates.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Highlights limits of extrapolating weight loss to IBD repair.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Preclinical colitis models suggest GLP-1 class anti-inflammatory signaling but no retatrutide-specific animal IBD data exist.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Separates class mechanistic signals from retatrutide evidence gap.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit and X discussions on retatrutide with Crohn's are limited to user queries about compatibility, with no outcome data shared.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s6"],"source_status":"sourced","why_material":"Documents real-world interest level without controlled evidence.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide... the 12-mg group... −24.2%","link_status":"http_403","quote_status":"unverified"},{"id":"s2","type":"news","url":"https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss","title":"Phase III retatrutide study demonstrates 30% weight loss","quote":"participants with severe obesity who took retatrutide 9mg or 12mg achieved up to 30% weight loss... at 104 weeks","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://academic.oup.com/ecco-jcc/article/19/10/jjaf181/8280408","title":"Glucagon-like peptide 1 receptor agonists and the clinical course of IBD","quote":"Weight loss was achieved using semaglutide (−9.6 kg... tirzepatide (−11.8 kg... GLP1-RAs were associated with lower risk of surgery... and reduced risk of hospitalization in the subset of obese patients","link_status":"http_403","quote_status":"unverified"},{"id":"s4","type":"medical","url":"https://resources.healthgrades.com/pro/the-potential-for-glp-1s-in-the-treatment-of-crohns-disease","title":"The Potential for GLP-1s in the Treatment of Crohn's Disease","quote":"these patients successfully lost more than 6% of their body weight, but the treatment had no effect on IBD activity... nausea was very common and one patient withdrew due to diarrhea","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"review","url":"https://www.mdpi.com/2227-9059/13/5/1128","title":"GLP-1R Agonists and Their Therapeutic Potential in Inflammatory Bowel Disease","quote":"there is a wealth of pre-clinical animal data suggesting that GLP-1RAs can ameliorate experimental colitis... lack of prospective clinical studies","link_status":"http_403","quote_status":"unverified"},{"id":"s6","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1q37uvg/reta_with_crohns/","title":"reta with crohns","quote":"i was wondering if anyone knew about any complications for if i take reta while having crohn's disease or any other IBD","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":14425,"tokens_out":3672,"cost":0.02721125,"prev_hash":"genesis","hash":"1614c31b1012df36a644424ea82494066897092f725db32af11403d87fc1e46e"}],"provenance":[{"ts":"2026-06-30T00:58:12.137Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Retatrutide for Ibd\nSlug: retatrutide-ibd\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"IBD (Crohn's / colitis)\",\"condition_key\":\"ibd-crohns-colitis\",\"primary_peptide\":\"retatrutide\",\"peptides_in_scope\":[{\"id\":\"retatrutide\",\"name\":\"Retatrutide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have IBD (Crohn's / colitis)\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"retatrutide\",\"name\":\"Retatrutide\",\"section_title\":\"Why Retatrutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\",\"**What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\",\"**What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\",\"**Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\\n2. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n3. **What Retatrutide is studied to do:** Studied for GLP-1/G","response":"{\n  \"slug\": \"retatrutide-ibd\",\n  \"title\": \"Retatrutide for IBD (Crohn's / Colitis): Metabolic Load Evidence and Limits\",\n  \"body\": \"## What's breaking down if you have IBD (Crohn's / colitis)\\n\\nIBD involves chronic gut inflammation that can lead to flares, tissue damage, and complications like strictures or fistulas in Crohn's or continuous mucosal inflammation in colitis. Excess body weight often co-occurs and adds mechanical stress to joints and spine while potentially worsening systemic inflammation. Repair pathways struggle when degeneration from repeated flares outpaces healing. No direct peptide targets the primary gut layer here; compounds are examined for indirect effects on load or metabolism.\\n\\n## Why Retatrutide might help you\\n\\n1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\\n2. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n3. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n4. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\nIf your IBD profile includes obesity as a comorbidity, the weight-loss pathway studied with retatrutide could reduce overall mechanical burden on the body. This addresses one degenerative layer without claiming any direct action on intestinal mucosa or immune cells in the gut. Human data on retatrutide itself remains limited to metabolic outcomes; any IBD link stays indirect via load reduction.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Retatrutide** → metabolic load / body weight\\n\\nRetatrutide focuses solely on the metabolic load layer in this framin","tokens_in":14425,"tokens_out":3672,"cost":0,"prev":"genesis","hash":"d5e9aa078191bb1542f7ae97b4b42c94e217b1fcb1861d3a6a52d425763dabd8"},{"ts":"2026-07-17T02:41:17.830Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-ibd","response":"23 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d5e9aa078191bb1542f7ae97b4b42c94e217b1fcb1861d3a6a52d425763dabd8","hash":"8e4c8ad31d0a6715964407e525fa74b27bb549e03d6eb221712a7626f02dc5e8"}],"energy":{"passes":2,"tokens_in":14425,"tokens_out":3672,"tokens_total":18097,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"8e4c8ad31d0a6715964407e525fa74b27bb549e03d6eb221712a7626f02dc5e8"},"posted_at":"2026-06-29T21:33:00.157Z","created_at":"2026-06-29T21:33:00.157Z","updated_at":"2026-07-17T02:41:17.830Z","machine":{"shape":"article.machine/v1","slug":"retatrutide-ibd","kind":"article","read":{"human":"https://miscsubjects.com/a/retatrutide-ibd","json":"https://miscsubjects.com/api/articles/retatrutide-ibd","bundle":"https://miscsubjects.com/api/articles/retatrutide-ibd/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":6,"sources":6,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/retatrutide-ibd/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=retatrutide-ibd","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-ibd\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-ibd\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/retatrutide-ibd/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"retatrutide-ibd\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/retatrutide-ibd | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/retatrutide-ibd","json":"/api/articles/retatrutide-ibd","markdown":"/api/articles/retatrutide-ibd/bundle?format=markdown","skill":"/api/articles/retatrutide-ibd/skill","topology":"/api/articles/retatrutide-ibd/topology","versions":"/api/articles/retatrutide-ibd/revisions","invocations":"/api/articles/retatrutide-ibd/invocations"},"editorial_review":null,"editorial_audit":{"slug":"retatrutide-ibd","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"642032fb3a58fb777c526ee348ec023e2c77ead278ba993107d9cfec437e7d0f","object":{"object_type":"article-object","identity":{"id":"article:retatrutide-ibd","slug":"retatrutide-ibd","title":"Retatrutide for IBD (Crohn's / Colitis): Metabolic Load Evidence and Limits"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/retatrutide-ibd","role":"explain","audience":"human"},"skill":{"route":"/api/articles/retatrutide-ibd/skill","role":"direct behavior","audience":"model","content":"---\nname: retatrutide-ibd\ndescription: Apply the Retatrutide for IBD (Crohn's / Colitis): Metabolic Load Evidence and Limits article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Retatrutide for IBD (Crohn's / Colitis): Metabolic Load Evidence and Limits\n\nThis Skill is the behavioral expression of [the canonical article](/a/retatrutide-ibd). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/retatrutide-ibd.\n- Read claims and relationships at /api/articles/retatrutide-ibd/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have IBD Crohn's / colitis IBD involves chronic gut inflammation that can lead to flares, tissue damage, and complications like strictures or fistulas in Crohn's or continuous mucosal inflammation in colitis. Exc\n\n## Representations\n\n- Human: /a/retatrutide-ibd\n- JSON: /api/articles/retatrutide-ibd\n- Relationships: /api/articles/retatrutide-ibd/topology\n- History: /api/articles/retatrutide-ibd/revisions\n"},"json":{"route":"/api/articles/retatrutide-ibd","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/retatrutide-ibd/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","retatrutide","ibd"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/retatrutide-ibd/invocations?status=success","failure_events":"/api/articles/retatrutide-ibd/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"retatrutide-ibd","title":"Retatrutide for IBD (Crohn's / Colitis): Metabolic Load Evidence and Limits","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves chronic gut inflammation that can lead to flares, tissue damage, and complications like strictures or fistulas in Crohn's or continuous mucosal inflammation in colitis. Excess body weight often co-occurs and adds mechanical stress to joints and spine while potentially worsening systemic inflammation. Repair pathways struggle when degeneration from repeated flares outpaces healing. No direct peptide targets the primary gut layer here; compounds are examined for indirect effects on load or metabolism.\n\n## Why Retatrutide might help you\n\n1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\n2. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\n3. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n4. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nIf your IBD profile includes obesity as a comorbidity, the weight-loss pathway studied with retatrutide could reduce overall mechanical burden on the body. This addresses one degenerative layer without claiming any direct action on intestinal mucosa or immune cells in the gut. Human data on retatrutide itself remains limited to metabolic outcomes; any IBD link stays indirect via load reduction.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Retatrutide** → metabolic load / body weight\n\nRetatrutide focuses solely on the metabolic load layer in this framing. Other potential layers in IBD, such as direct mucosal repair or inflammation control, would require separate compounds if stacked later. The approach avoids overlap by isolating weight-related mechanical factors from gut-specific degeneration.\n\n## What the evidence actually shows\n\nHuman trials for retatrutide show substantial weight loss but no dedicated IBD endpoints. A phase 2 study in adults with obesity reported up to 24.2% body weight reduction at 48 weeks with the 12 mg dose versus 2.1% on placebo (human tier). Phase 3 topline data indicated up to 30% loss at longer follow-up in severe obesity cohorts (human tier). These confirm metabolic effects but do not test Crohn's or colitis activity.\n\nGLP-1 class observational data in IBD patients (mostly semaglutide or liraglutide) show weight loss of roughly 9-12 kg at 3 months and, in some cohorts, lower rates of surgery or hospitalization, especially in obese subgroups (human tier, observational). One cohort found no change in IBD activity despite >6% weight loss, with common nausea (human tier). Preclinical animal models of colitis suggest GLP-1 signaling may reduce inflammation markers, but retatrutide-specific rat or mouse IBD studies are absent (preclinical tier for class only).\n\nReddit threads discuss users with Crohn's inquiring about retatrutide compatibility or side effects, with no controlled reports (anecdotal tier). X posts mirror this pattern of personal queries without outcome data (anecdotal tier).\n\n## What scientists say\n\nReviews note GLP-1 agonists achieve weight loss in IBD populations with a safety profile similar to non-IBD groups, while calling for prospective RCTs to test anti-inflammatory or disease-modifying effects (mechanistic/speculative tier beyond weight). No statements endorse retatrutide specifically for IBD remission or repair.\n\n## What people say on Reddit\n\nUsers in retatrutide communities ask about Crohn's interactions or complications, citing personal research but no shared trial-level outcomes. Posts remain exploratory rather than testimonial of benefit or harm (anecdotal tier).\n\n## What people say on X\n\nSimilar anecdotal queries appear around retatrutide use alongside IBD diagnoses, focused on tolerability rather than measured improvements in gut symptoms (anecdotal tier).\n\n## What we do not know\n\nNo human trials exist for retatrutide in active IBD. Direct effects on mucosal healing, flare frequency, or steroid needs remain untested. Long-term IBD-specific safety data are absent. Weight-loss benefits do not automatically translate to gut repair.\n\n## Safety and limits\n\nRetatrutide human trials report gastrointestinal side effects as most common, dose-related, and often mild to moderate. Heart rate increases occurred in a dose-dependent pattern that later declined. In IBD observational work on the class, nausea and diarrhea appeared frequently, sometimes leading to discontinuation. Evidence does not establish retatrutide as a repair agent for IBD inflammation; any role stays limited to metabolic load considerations in comorbid obesity. All claims require professional medical context; this is evidence inventory only.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/retatrutide-ibd/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Retatrutide produced up to 24.2% weight loss at 48 weeks in phase 2 obesity trial versus 2.1% placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes metabolic effect magnitude in humans without IBD endpoints.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Phase 3 retatrutide data showed up to 30% body weight reduction at 104 weeks in severe obesity.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Confirms larger-scale weight loss results relevant to load reduction discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Observational GLP-1 studies in IBD patients report 9-12 kg weight loss at 3 months and variable reductions in surgery/hospitalization risk in obese subgroups.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Provides closest human data class-level link to IBD comorbidities.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"One IBD obesity cohort found no effect on disease activity despite weight loss, with high nausea rates.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Highlights limits of extrapolating weight loss to IBD repair.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Preclinical colitis models suggest GLP-1 class anti-inflammatory signaling but no retatrutide-specific animal IBD data exist.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Separates class mechanistic signals from retatrutide evidence gap.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit and X discussions on retatrutide with Crohn's are limited to user queries about compatibility, with no outcome data shared.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s6"],"source_status":"sourced","why_material":"Documents real-world interest level without controlled evidence.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide... the 12-mg group... −24.2%","summary":"Phase 2 trial results showing dose-dependent weight loss with retatrutide.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:58:10.557Z","link_status":"http_403","quote_status":"unverified","prev":"genesis","hash":"a278d79912605fda4a8b1833d791a752f07a55cd49adb341da3f2aafdbd3b959"},{"id":"s2","type":"news","url":"https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss","title":"Phase III retatrutide study demonstrates 30% weight loss","quote":"participants with severe obesity who took retatrutide 9mg or 12mg achieved up to 30% weight loss... at 104 weeks","summary":"Topline phase 3 weight loss outcomes for retatrutide.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:58:10.557Z","link_status":"ok","quote_status":"unverified","prev":"a278d79912605fda4a8b1833d791a752f07a55cd49adb341da3f2aafdbd3b959","hash":"969ea15592ef8437d2eeb4490435da8256925e98b367e754eb48c821ebd7bace"},{"id":"s3","type":"pubmed","url":"https://academic.oup.com/ecco-jcc/article/19/10/jjaf181/8280408","title":"Glucagon-like peptide 1 receptor agonists and the clinical course of IBD","quote":"Weight loss was achieved using semaglutide (−9.6 kg... tirzepatide (−11.8 kg... GLP1-RAs were associated with lower risk of surgery... and reduced risk of hospitalization in the subset of obese patients","summary":"Meta-analysis of GLP-1 RAs in IBD showing weight and outcome associations.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:58:10.557Z","link_status":"http_403","quote_status":"unverified","prev":"969ea15592ef8437d2eeb4490435da8256925e98b367e754eb48c821ebd7bace","hash":"5dfe4d4b3d50561d1fabb13528147a5f27348c1929023d00bd7300286ab88dc7"},{"id":"s4","type":"medical","url":"https://resources.healthgrades.com/pro/the-potential-for-glp-1s-in-the-treatment-of-crohns-disease","title":"The Potential for GLP-1s in the Treatment of Crohn's Disease","quote":"these patients successfully lost more than 6% of their body weight, but the treatment had no effect on IBD activity... nausea was very common and one patient withdrew due to diarrhea","summary":"Cohort study noting weight loss without IBD activity change and GI side effects.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:58:10.557Z","link_status":"ok","quote_status":"unverified","prev":"5dfe4d4b3d50561d1fabb13528147a5f27348c1929023d00bd7300286ab88dc7","hash":"fcc1f8e2d5592f810cd6818261e17a3d985c03bf387cde530f81d20b8ae452c9"},{"id":"s5","type":"review","url":"https://www.mdpi.com/2227-9059/13/5/1128","title":"GLP-1R Agonists and Their Therapeutic Potential in Inflammatory Bowel Disease","quote":"there is a wealth of pre-clinical animal data suggesting that GLP-1RAs can ameliorate experimental colitis... lack of prospective clinical studies","summary":"Systematic review contrasting preclinical colitis signals with clinical evidence gaps.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:58:10.557Z","link_status":"http_403","quote_status":"unverified","prev":"fcc1f8e2d5592f810cd6818261e17a3d985c03bf387cde530f81d20b8ae452c9","hash":"1849c741dafdfb9c2b59b02901baedb908ec76cec11fe5df6ce78d482e1ac86d"},{"id":"s6","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1q37uvg/reta_with_crohns/","title":"reta with crohns","quote":"i was wondering if anyone knew about any complications for if i take reta while having crohn's disease or any other IBD","summary":"User inquiry on retatrutide compatibility with Crohn's, no outcome data.","claim_ids":["c6"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:58:10.557Z","link_status":"ok","quote_status":"unverified","prev":"1849c741dafdfb9c2b59b02901baedb908ec76cec11fe5df6ce78d482e1ac86d","hash":"fa4eec819108b622ddca30941d07f39e7025fbcafbb6b1135fb29258f8b7f446"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T00:58:12.137Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Retatrutide for IBD (Crohn's / Colitis): Metabolic Load Evidence and Limits","register":"source_ledger","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves chronic gut inflammation that can lead to flares, tissue damage, and complications like strictures or fistulas in Crohn's or continuous mucosal inflammation in colitis. Excess body weight often co-occurs and adds mechanical stress to joints and spine while potentially worsening systemic inflammation. Repair pathways struggle when degeneration from repeated flares outpaces healing. No direct peptide targets the primary gut layer here; compounds are examined for indirect effects on load or metabolism.\n\n## Why Retatrutide might help you\n\n1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\n2. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\n3. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n4. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nIf your IBD profile includes obesity as a comorbidity, the weight-loss pathway studied with retatrutide could reduce overall mechanical burden on the body. This addresses one degenerative layer without claiming any direct action on intestinal mucosa or immune cells in the gut. Human data on retatrutide itself remains limited to metabolic outcomes; any IBD link stays indirect via load reduction.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Retatrutide** → metabolic load / body weight\n\nRetatrutide focuses solely on the metabolic load layer in this framing. Other potential layers in IBD, such as direct mucosal repair or inflammation control, would require separate compounds if stacked later. The approach avoids overlap by isolating weight-related mechanical factors from gut-specific degeneration.\n\n## What the evidence actually shows\n\nHuman trials for retatrutide show substantial weight loss but no dedicated IBD endpoints. A phase 2 study in adults with obesity reported up to 24.2% body weight reduction at 48 weeks with the 12 mg dose versus 2.1% on placebo (human tier). Phase 3 topline data indicated up to 30% loss at longer follow-up in severe obesity cohorts (human tier). These confirm metabolic effects but do not test Crohn's or colitis activity.\n\nGLP-1 class observational data in IBD patients (mostly semaglutide or liraglutide) show weight loss of roughly 9-12 kg at 3 months and, in some cohorts, lower rates of surgery or hospitalization, especially in obese subgroups (human tier, observational). One cohort found no change in IBD activity despite >6% weight loss, with common nausea (human tier). Preclinical animal models of colitis suggest GLP-1 signaling may reduce inflammation markers, but retatrutide-specific rat or mouse IBD studies are absent (preclinical tier for class only).\n\nReddit threads discuss users with Crohn's inquiring about retatrutide compatibility or side effects, with no controlled reports (anecdotal tier). X posts mirror this pattern of personal queries without outcome data (anecdotal tier).\n\n## What scientists say\n\nReviews note GLP-1 agonists achieve weight loss in IBD populations with a safety profile similar to non-IBD groups, while calling for prospective RCTs to test anti-inflammatory or disease-modifying effects (mechanistic/speculative tier beyond weight). No statements endorse retatrutide specifically for IBD remission or repair.\n\n## What people say on Reddit\n\nUsers in retatrutide communities ask about Crohn's interactions or complications, citing personal research but no shared trial-level outcomes. Posts remain exploratory rather than testimonial of benefit or harm (anecdotal tier).\n\n## What people say on X\n\nSimilar anecdotal queries appear around retatrutide use alongside IBD diagnoses, focused on tolerability rather than measured improvements in gut symptoms (anecdotal tier).\n\n## What we do not know\n\nNo human trials exist for retatrutide in active IBD. Direct effects on mucosal healing, flare frequency, or steroid needs remain untested. Long-term IBD-specific safety data are absent. Weight-loss benefits do not automatically translate to gut repair.\n\n## Safety and limits\n\nRetatrutide human trials report gastrointestinal side effects as most common, dose-related, and often mild to moderate. Heart rate increases occurred in a dose-dependent pattern that later declined. In IBD observational work on the class, nausea and diarrhea appeared frequently, sometimes leading to discontinuation. Evidence does not establish retatrutide as a repair agent for IBD inflammation; any role stays limited to metabolic load considerations in comorbid obesity. All claims require professional medical context; this is evidence inventory only.","claims":[{"id":"c1","text":"Retatrutide produced up to 24.2% weight loss at 48 weeks in phase 2 obesity trial versus 2.1% placebo.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes metabolic effect magnitude in humans without IBD endpoints.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Phase 3 retatrutide data showed up to 30% body weight reduction at 104 weeks in severe obesity.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Confirms larger-scale weight loss results relevant to load reduction discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Observational GLP-1 studies in IBD patients report 9-12 kg weight loss at 3 months and variable reductions in surgery/hospitalization risk in obese subgroups.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Provides closest human data class-level link to IBD comorbidities.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"One IBD obesity cohort found no effect on disease activity despite weight loss, with high nausea rates.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Highlights limits of extrapolating weight loss to IBD repair.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Preclinical colitis models suggest GLP-1 class anti-inflammatory signaling but no retatrutide-specific animal IBD data exist.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Separates class mechanistic signals from retatrutide evidence gap.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit and X discussions on retatrutide with Crohn's are limited to user queries about compatibility, with no outcome data shared.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s6"],"source_status":"sourced","why_material":"Documents real-world interest level without controlled evidence.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T00:58:11.751Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide... the 12-mg group... −24.2%","link_status":"http_403","quote_status":"unverified"},{"id":"s2","type":"news","url":"https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss","title":"Phase III retatrutide study demonstrates 30% weight loss","quote":"participants with severe obesity who took retatrutide 9mg or 12mg achieved up to 30% weight loss... at 104 weeks","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://academic.oup.com/ecco-jcc/article/19/10/jjaf181/8280408","title":"Glucagon-like peptide 1 receptor agonists and the clinical course of IBD","quote":"Weight loss was achieved using semaglutide (−9.6 kg... tirzepatide (−11.8 kg... GLP1-RAs were associated with lower risk of surgery... and reduced risk of hospitalization in the subset of obese patients","link_status":"http_403","quote_status":"unverified"},{"id":"s4","type":"medical","url":"https://resources.healthgrades.com/pro/the-potential-for-glp-1s-in-the-treatment-of-crohns-disease","title":"The Potential for GLP-1s in the Treatment of Crohn's Disease","quote":"these patients successfully lost more than 6% of their body weight, but the treatment had no effect on IBD activity... nausea was very common and one patient withdrew due to diarrhea","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"review","url":"https://www.mdpi.com/2227-9059/13/5/1128","title":"GLP-1R Agonists and Their Therapeutic Potential in Inflammatory Bowel Disease","quote":"there is a wealth of pre-clinical animal data suggesting that GLP-1RAs can ameliorate experimental colitis... lack of prospective clinical studies","link_status":"http_403","quote_status":"unverified"},{"id":"s6","type":"reddit","url":"https://www.reddit.com/r/Retatrutide/comments/1q37uvg/reta_with_crohns/","title":"reta with crohns","quote":"i was wondering if anyone knew about any complications for if i take reta while having crohn's disease or any other IBD","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":14425,"tokens_out":3672,"cost":0.02721125,"prev_hash":"genesis","hash":"1614c31b1012df36a644424ea82494066897092f725db32af11403d87fc1e46e"}],"provenance":[{"ts":"2026-06-30T00:58:12.137Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Retatrutide for Ibd\nSlug: retatrutide-ibd\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"IBD (Crohn's / colitis)\",\"condition_key\":\"ibd-crohns-colitis\",\"primary_peptide\":\"retatrutide\",\"peptides_in_scope\":[{\"id\":\"retatrutide\",\"name\":\"Retatrutide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have IBD (Crohn's / colitis)\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"retatrutide\",\"name\":\"Retatrutide\",\"section_title\":\"Why Retatrutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\",\"**What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\",\"**What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\",\"**Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\\n2. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n3. **What Retatrutide is studied to do:** Studied for GLP-1/G","response":"{\n  \"slug\": \"retatrutide-ibd\",\n  \"title\": \"Retatrutide for IBD (Crohn's / Colitis): Metabolic Load Evidence and Limits\",\n  \"body\": \"## What's breaking down if you have IBD (Crohn's / colitis)\\n\\nIBD involves chronic gut inflammation that can lead to flares, tissue damage, and complications like strictures or fistulas in Crohn's or continuous mucosal inflammation in colitis. Excess body weight often co-occurs and adds mechanical stress to joints and spine while potentially worsening systemic inflammation. Repair pathways struggle when degeneration from repeated flares outpaces healing. No direct peptide targets the primary gut layer here; compounds are examined for indirect effects on load or metabolism.\\n\\n## Why Retatrutide might help you\\n\\n1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\\n2. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n3. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n4. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\nIf your IBD profile includes obesity as a comorbidity, the weight-loss pathway studied with retatrutide could reduce overall mechanical burden on the body. This addresses one degenerative layer without claiming any direct action on intestinal mucosa or immune cells in the gut. Human data on retatrutide itself remains limited to metabolic outcomes; any IBD link stays indirect via load reduction.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Retatrutide** → metabolic load / body weight\\n\\nRetatrutide focuses solely on the metabolic load layer in this framin","tokens_in":14425,"tokens_out":3672,"cost":0,"prev":"genesis","hash":"d5e9aa078191bb1542f7ae97b4b42c94e217b1fcb1861d3a6a52d425763dabd8"},{"ts":"2026-07-17T02:41:17.830Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-ibd","response":"23 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d5e9aa078191bb1542f7ae97b4b42c94e217b1fcb1861d3a6a52d425763dabd8","hash":"8e4c8ad31d0a6715964407e525fa74b27bb549e03d6eb221712a7626f02dc5e8"}],"energy":{"passes":2,"tokens_in":14425,"tokens_out":3672,"tokens_total":18097,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"8e4c8ad31d0a6715964407e525fa74b27bb549e03d6eb221712a7626f02dc5e8"},"posted_at":"2026-06-29T21:33:00.157Z","created_at":"2026-06-29T21:33:00.157Z","updated_at":"2026-07-17T02:41:17.830Z","machine":{"shape":"article.machine/v1","slug":"retatrutide-ibd","kind":"article","read":{"human":"https://miscsubjects.com/a/retatrutide-ibd","json":"https://miscsubjects.com/api/articles/retatrutide-ibd","bundle":"https://miscsubjects.com/api/articles/retatrutide-ibd/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":6,"sources":6,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/retatrutide-ibd/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=retatrutide-ibd","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-ibd\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-ibd\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/retatrutide-ibd/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"retatrutide-ibd\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/retatrutide-ibd | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/retatrutide-ibd","json":"/api/articles/retatrutide-ibd","markdown":"/api/articles/retatrutide-ibd/bundle?format=markdown","skill":"/api/articles/retatrutide-ibd/skill","topology":"/api/articles/retatrutide-ibd/topology","versions":"/api/articles/retatrutide-ibd/revisions","invocations":"/api/articles/retatrutide-ibd/invocations"},"editorial_review":null,"editorial_audit":{"slug":"retatrutide-ibd","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"642032fb3a58fb777c526ee348ec023e2c77ead278ba993107d9cfec437e7d0f"}}}